Key Considerations When Partnering with a CDMO for Your Plasma-Derived Therapies

Plasma contains an array of beneficial constituents that, when purified and concentrated, can be administered as medicines to treat rare and complex diseases. The generation of complex plasma proteins is something that animals have developed over the course of evolution. For drug development, skill and expertise is required to isolate these proteins from the blood and purify them into commercially viable and effective concentrations – in a safe, controlled manner that does not damage or destroy their unique structure and properties.

In a recent article published in The Medicine Maker, experts from Emergent break down the qualities that make an ideal external partner for plasma- based protein manufacturing and discuss what questions to consider when selecting a CDMO.